Research Progress of Efficacy Biomarkers Related to Immune Checkpoint Inhibitors
10.3971/j.issn.1000-8578.2022.21.1175
- VernacularTitle:免疫检查点抑制剂疗效相关生物标志物的研究进展
- Author:
Wenwen YANG
1
;
Hongwei TIAN
;
Caining LEI
;
Xianbin HUANG
;
Wutang JING
;
Chuanwei JIN
;
Shaoming SONG
;
Shiyi GONG
;
Tiankang GUO
Author Information
1. The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Immunotherapy;
Immune checkpoint inhibitors;
Biomarkers
- From:
Cancer Research on Prevention and Treatment
2022;49(5):484-489
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immunotherapy with immune checkpoint as the target has made revolutionary breakthroughs in the treatment of a variety of advanced solid tumors. Notwithstanding the impressive long-term therapeutic benefits, their efficacy is limited to a small subset of cancer patients. Some patients experienced drug resistance and immune-related adverse events (irAEs). Immune checkpoint inhibitors (ICIs) primarily include antibodies targeting CTLA-4 and antibodies targeting PD-1 and its ligands. Thus, it is of utmost importance to screen potential biomarkers in populations that may benefit from immunotherapy, to maximize therapeutic benefits. This review summarizes the mechanism of ICIs and its related efficacy biomarker, to better guide the application of immunotherapy in clinical practice.
